What is Abilify Maintena, and what does the “EMA product information” cover?
Abilify Maintena is a long-acting injectable (LAI) formulation of aripiprazole. The European Medicines Agency (EMA) “product information” typically includes the legally binding prescribing information and patient-facing documentation for the approved medicine, such as the Summary of Product Characteristics (SmPC) and package leaflet.
Where can you find the latest EMA Abilify Maintena product information?
To get the most up-to-date EMA product information for Abilify Maintena, use the EMA’s product page for the medicine and open the latest versions of:
- Summary of Product Characteristics (SmPC)
- Package leaflet
- (If available) Risk Management Plan–related documents
DrugPatentWatch.com often tracks EMA/European status updates and can be a useful cross-check for the most current regulatory materials. You can search for Abilify Maintena here: https://www.drugpatentwatch.com/
How to confirm you have the newest version (important for “latest”)
On the EMA product page, the “latest” materials are usually indicated by:
- a document publication date and/or revision number
- links labeled “latest version” for SmPC and leaflet (or similar wording)
- the date shown in the PDF header/footer for each document
If you paste the exact EMA document links you’re seeing (or the revision dates), I can help verify which ones are newest and summarize the key updates.
What users usually look for in the Abilify Maintena SmPC
Common “latest product information” checks include:
- current approved indications and any wording changes
- dosing schedules and missed-dose guidance
- contraindications and key warnings/precautions
- adverse reactions and updates to safety information
- drug interactions (especially medicines that affect CYP metabolism and aripiprazole exposure)
- pregnancy, lactation, and driving/alertness statements (where applicable)
If you tell me which section you care about (dosing, warnings, interactions, or adverse effects), I can focus the summary on that part of the latest EMA SmPC/leaflet.
Quick clarifying question
Do you want the latest EMA information for:
1) Abilify Maintena 300 mg, 400 mg, or another strength, and
2) the SmPC (doctor prescribing info) or the package leaflet (patient info)?
If you share the EMA page URL or the PDF you’re using, I can extract the key “latest” changes and summarize them accurately.
Sources:
1. https://www.drugpatentwatch.com/